Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: dates

Improvement of MVA-based Vaccines by Expression of an Autophagy Inhibitor

Anita Spindler, et al. XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016 Download the poster here Poster Presentation

Published 1 July 2016
Categorized as -others, 2016, Publication

Oncolytic vaccinia virus TG6002 demonstrates potent efficiency in pancreatic tumor alone and in combination with standard chemotherapies

Johann Foloppe, et al. XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016 Download the poster here Poster Presentation

Published 1 July 2016
Categorized as -others, 2016, Publication, TG6002

A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy

Ghassan K. Abou-Alfa, et al. ASCO Annual Meeting 2016, June 3-7, 2016, Chicago Illinois Download the poster here Poster Presentation

Published 6 June 2016
Categorized as -others, 2016, Pexa-Vec, Publication

Transgene Announces Poster Presentation at ASCO Annual Meeting on the Phase 3 PHOCUS Clinical Trial with Pexa-Vec Oncolytic Immunotherapy

20160531 – ASCO_Poster_PR_V2_clean

Published 31 May 2016
Categorized as 2016, Pexa-Vec, Press release

Composition of the Board of Directors and Statutory Auditors

20160525 – nomination Mr Beret – us

Published 25 May 2016
Categorized as 2016, Press release

Transgene Reports First Quarter 2016 Business Update

20160421 PR VEN Q1 2016 – V4 clean

Published 21 April 2016
Categorized as 2016, Press release

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition

Jean Baptiste Marchand, et al.XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016Download the poster herePoster Presentation

Published 19 April 2016
Categorized as -others, 2016, Invir.IO, Publication

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allow their intratumoral delivery and an improved tumor-growth inhibition

Jean Baptiste Marchand, et al. AACR Annual Meeting 2016, April 16-20, 2016, E.N. MorialConvention Center, New Orleans, Louisiana Download the poster here Poster Presentation

Published 19 April 2016
Categorized as -others, 2016, Publication

Transgene Presents Pre-Clinical Data at AACR on a New Generation Oncolytic Viral Immunotherapy Armed with an Anti-PD1 Monoclonal Antibody (poster)

20160419 AACR Poster PR Final

Published 19 April 2016
Categorized as 2016, Press release

Transgene Hires Two Senior Pharmaceutical Industry Executives to Join Leadership Team

20160317 Appointments PR Final

Published 17 March 2016
Categorized as 2016, Press release

Posts pagination

Newer posts Page 1 … Page 41 … Page 47 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu